Interaction of mesalasine (5-ASA) with translational initiation factors eIF4 partially explains 5-ASA anti-inflammatory and anti-neoplastic activities

Medicinal Chemistry

Volumn 7, Issue 2, 2011, Pages 92-98

  Lyakhovich, Alex ^a,e   Michlmayr, Anna ^b   Bakulina, Anastasia ^c   Gerner, Christopher ^d   Oehler, Rudolf ^b   Gasche, Christoph ^a  

^a INSTITUTE FOR MICROELECTRONICS   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c STATE RESEARCH CENTER OF VIROLOGY AND BIOTECHNOLOGY VECTOR   (Russian Federation)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

2D DIGE; 5 ASA; Chemogenomics; IBD; Mesalazine; OMICs

Indexed keywords

BETA CATENIN; CAP BINDING PROTEIN; INITIATION FACTOR 4B; INITIATION FACTOR 4E; MESALAZINE; WNT PROTEIN;

ANTIGEN ANTIBODY COMPLEX; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; HUMAN; HUMAN CELL; MOLECULAR DOCKING; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS INHIBITION; RETICULOCYTE; SURFACE PLASMON RESONANCE;

EID: 79952335251     PISSN: 15734064     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340611794859325     Document Type: Article

References (38)

1. Andrews, J.M., Travis, S.P., Gibson, P.R., Gasche, C. Systematic review: does concurrent therapy with 5-ASA and immunomodulators in inflammatory bowel disease improve outcomes? Aliment Pharmacol Ther., 2009, 29(5), 459-469.
2. Nielsen, O.H., Munck, L.K. Drug insight: aminosalicylates for the treatment of IBD. Nat. Clin. Pract. Gastroenterol. Hepatol., 2007, 4(3), 160-170. (Pubitemid 46416252)
3. Half, E., Arber, N. Colon cancer: preventive agents and the present status of chemoprevention. Expert Opin. Pharmacother., 2009, 10(2), 211-219.
4. Velayos, F.S., Terdiman, J.P., Walsh, J.M. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am. J. Gastroenterol., 2005, 100(6), 1345-1253.
5. Rubin, D.T., Cruz-Correa, M.R., Gasche, C., Jass, J.R., Lichtenstein, G.R., Montgomery, E.A., Riddell, R.H., Rutter, M.D., Ullman, T.A., Velayos, F.S., Itzkowitz, S. Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update. Inflamm. Bowel Dis., 2008, 14(2), 265-274. (Pubitemid 351288050)
6. Chau, I., Cunningham, D. Treatment in advanced colorectal cancer: what, when and how? Br. J. Cancer, 2009, 100(11), 1704-1719.
7. Stolfi, C., Pellegrini, R., Franze, E., Pallone, F., Monteleone, G. Molecular basis of the potential of mesalazine to prevent colorectal cancer. World J. Gastroenterol., 2008, 14(28), 4434-4439.
8. Lyakhovich, A., Gasche, C. Systematic review: molecular chemoprevention of colorectal malignancy by mesalazine. Aliment Pharmacol. Ther., 2010, 31(2), 202-209.
9. Campregher, C., Luciani, M.G., Biesenbach, P., Evstatiev, R., Lyakhovich, A., Gasche, C. The position of the amino group on the benzene ring is critical for mesalamine's improvement of replication fidelity. Inflamm. Bowel Dis., 2010, 16(4), 576-582.
10. Ornstein, D.K., Petricoin, E.F. III. Proteomics to diagnose human tumors and provide prognostic information. Oncology (Williston Park), 2004, 18(4), 521-529.
11. Unlu, M., Morgan, M.E., Minden, J.S. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis, 1997, 18(11), 2071-207.
12. Gaither, L.A. Chemogenomics approaches to novel target discovery. Expert Rev. Proteomics, 2007, 4(3), 411-419. (Pubitemid 46890078)
13. Smith, C. Drug discovery in reverse. Nature, 2004, 428(6979), 227.
14. Bogliolo, M., Lyakhovich, A., Callén, E., Castellà, M., Cappelli, E., Ramírez, M.J., Creus, A., Marcos, R., Kalb, R., Neveling, K., Schindler, D., Surrallés, J. Histone H2AX and Fanconi anemia FANCD2 function in the same pathway to maintain chromosome stability. EMBO J., 2007, 26(5), 1340-1351. (Pubitemid 46398698)
15. Shevchenko, A., Wilm, M., Vorm, O., Mann, M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem., 1996, 68(5), 850-858.
16. Lyakhovich, A., Shekhar, M.P. Supramolecular complex formation between Rad6 and proteins of the p53 pathway during DNA damage-induced response. Mol. Cell Biol., 2003, 23(7), 2463-2475. (Pubitemid 36351027)
17. Suragani, R.N., Ghosh, S., Ehtesham, N.Z., Ehtesham, N.Z., Ramaiah, K.V. Expression and purification of the subunits of human translational initiation factor 2 (eIF2): phosphorylation of eIF2 alpha and beta. Protein Expr. Purif., 2006, 47(1), 225-233.
18. Ramaiah, K.V., Dhindsa, R.S., Chen, J.J., London, I.M., Levin, D. Recycling and phosphorylation of eukaryotic initiation factor 2 on 60S subunits of 80S initiation complexes and polysomes. Proc. Natl. Acad. Sci. USA, 1992, 89(24), 12063-12067. (Pubitemid 23004785)
19. Surolia, N., Padmanaban, G. Chloroquine inhibits heme-dependent protein synthesis in Plasmodium falciparum. Proc. Natl. Acad. Sci. USA, 1991, 88(11), 4786-4790. (Pubitemid 21914627)
20. Tomoo, K., Shen, X., Okabe, K., Nozoe, Y., Fukuhara, S., Morino, S., Ishida, T., Taniguchi, T., Hasegawa, H., Terashima, A., Sasaki, M., Katsuya, Y., Kitamura, K., Miyoshi, H., Ishikawa, M., Miura, K. Crystal structures of 7-methylguanosine 5'-triphosphate (m(7)GTP)- and P(1)-7-methylguanosine-P(3)- adenosine-5',5'-triphosphate (m(7) GpppA)-bound human full-length eukaryotic initiation factor 4E: biological importance of the C-terminal flexible region. Biochem. J., 2002, 362(Pt 3), 539-544. (Pubitemid 34242303)
21. Borawski, J., Lindeman, A., Buxton, F., Labow, M., Gaither, L.A. Optimization procedure for small interfering RNA transfection in a 384-well format. J. Biomol. Screen., 2007, 12(4), 546-559. (Pubitemid 46871827)
22. Vidal, M., Endoh, H. Prospects for drug screening using the reverse two-hybrid system. Trends Biotechnol., 1999, 17(9), 374-381. (Pubitemid 29378277)
23. Garas, A., Webb, E., Pillay, V., MacPhee, D., Denny, W., Zeller, H., Cotton, R. A novel and simple method of screening compounds for interaction with DNA: A validation study. Mutat. Res., 2009, 678(1), 20-29.
24. Cui, F.L., Qin, L.X., Li, F., Luo X.H. Synchronous fluorescence determination and molecular modeling of 5-Aminosalicylic acid (5-ASA) interacted with human serum albumin. J. Mol. Model., 2008, 14(12), 1111-1117.
25. Rousseaux, C., Lefebvre, B., Dubuquoy, L., Lefebvre, P., Romano, O., Auwerx, J., Metzger, D., Wahli, W., Desvergne, B., Naccari, G.C., Chavatte, P., Farce, A., Bulois, P., Cortot, A., Colombel, J.F., Desreumaux, P. Intestinal antiinflammatory effect of 5- aminosalicylic acid is dependent on peroxisome proliferatoractivated receptor-gamma. J. Exp. Med., 2005, 201(8), 1205-1215. (Pubitemid 40629065)
26. Liotta, L.A., Steeg, P.S., Stetler-Stevenson, W.G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 1991, 64(2), 327-336. (Pubitemid 121001258)
27. William, W.N., Jr., Heymach, J.V., Kim, E.S., Lippman, S.M. Molecular targets for cancer chemoprevention. Nat. Rev. Drug Discov., 2009, 8(3), 213-225.
28. Cuzick, J., Otto, F., Baron, J.A., Brown, P.H., Burn, J., Greenwald, P., Jankowski, J., La Vecchia, C., Meyskens, F., Senn, H.J., Thun, M. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol., 2009, 10(5), 501-507.
29. Wilkie, G.S., Dickson, K.S., Gray, N.K. Regulation of mRNA translation by 5'- and 3'-UTR-binding factors. Trends Biochem. Sci., 2003, 28(4), 182-188. (Pubitemid 36507156)
30. Robert, F., Pelletier, J. Translation initiation: a critical signalling node in cancer. Expert Opin. Ther. Targets, 2009; 13(11), 1279-1293.
31. Assouline, S., Culjkovic, B., Cocolakis, E., Rousseau, C., Beslu, N., Amri, A., Caplan, S., Leber, B., Roy, D.C., Miller, W.H. Jr., Borden, K.L. Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood, 2009, 114(2), 257-260.
32. Inamdar, K.V., Romaguera, J.E., Drakos, E., Knoblock, R.J., Garcia, M., Leventaki, V., Medeiros, L.J., Rassidakis, G.Z. Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine. Cancer, 2009, 115(20), 4727-4736.
33. Fischer, P.M. Cap in hand: targeting eIF4E. Cell Cycle, 2009, 8(16), 2535-2541.
34. Borden, K.L. Tissue targeting in cancer: eIF4E's tale. Clin. Cancer Res., 2009, 15(13), 4254-4255.
35. Rodnina, M.V., Wintermeyer, W. Recent mechanistic insights into eukaryotic ribosomes. Curr. Opin. Cell Biol., 2009, 21(3), 435-443.
36. Methot, N., Song, M.S., Sonenberg, N. A region rich in aspartic acid, arginine, tyrosine, and glycine (DRYG) mediates eukaryotic initiation factor 4B (eIF4B) self-association and interaction with eIF3. Mol. Cell Biol., 1996, 16(10), 5328-5334. (Pubitemid 26315051)
37. Swidsinski, A., Weber, J., Loening-Baucke, V., Hale, L.P., Lochs, H. Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J. Clin. Microbiol., 2005, 43(7), 3380-3389. (Pubitemid 40981351)
38. Round, J.L., Mazmanian, S.K. The gut microbiota shapes intestinal immune responses during health and disease. Nat. Rev. Immunol., 2009, 9(5), 313-323.